Table 3.
Meta-analysis results for IL-17F 7488T/C polymorphism
| Number of Studies | CC vs TT
|
TC vs TT
|
TC/CC vs TT
|
CC vs TT/TC
|
C vs T
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | Het | OR (95% CI) | Het | OR (95% CI) | Het | OR (95% CI) | Het | OR (95% CI) | Het | ||
| Total | 7 | 1.39 (1.03, 1.88)* | 0.979 | 1.02 (0.78, 1.33) | 0.001 | 1.05 (0.82, 1.35) | 0.001 | 1.35 (1.00, 1.82)* | 0.925 | 1.08 (0.90, 1.30) | 0.009 |
| Cancer types | |||||||||||
| GC | 3 | 1.49 (1.06, 2.10)* | 0.937 | 1.29 (1.00, 1.65)* | 0.18 | 1.33 (1.09, 1.64)* | 0.24 | 1.36 (0.97, 1.91) | 0.875 | 1.32 (1.15, 1.51)* | 0.466 |
| Others | 4 | 1.04 (0.53, 2.05) | 0.983 | 0.85 (0.61, 1.19) | 0.059 | 0.87 (0.64, 1.18) | 0.081 | 1.32 (0.70, 2.46) | 0.65 | 0.93 (0.75, 1.15) | 0.174 |
| HWE | |||||||||||
| Yes | 4 | 1.15 (0.61, 2.17) | 0.868 | 0.92 (0.71, 1.19) | 0.071 | 0.93 (0.73, 1.19) | 0.08 | 1.18 (0.62, 2.21) | 0.87 | 0.95 (0.77, 1.17) | 0.133 |
| No | 3 | 1.47 (1.04, 2.07)* | 0.989 | 1.29 (0.89, 1.88) | 0.176 | 1.38 (1.06, 1.79)* | 0.254 | 1.41 (1.00, 1.97)* | 0.598 | 1.34 (1.17, 1.55)* | 0.635 |
| Source of controls | |||||||||||
| PB | 5 | 1.37 (1.00, 1.87)* | 0.917 | 1.04 (0.76, 1.43) | 0.001 | 1.06 (0.79, 1.44) | <0.001 | 1.27 (0.93, 1.74) | 0.963 | 1.09 (0.83, 1.45) | 0.923 |
| HB | 2 | 1.69 (0.52, 5.42) | 0.771 | 0.90 (0.46, 1.77) | 0.251 | 1.00 (0.61, 1.61) | 0.295 | 2.39 (0.86, 6.64) | 0.664 | 1.07 (0.84, 1.37) | 0.002 |
Note:
*
Significant association.
Abbreviations: OR, odds ratio; CI, confidence interval; Het, P-value of heterogeneity; HB, hospital-based studies; PB, population-based studies; GC, gastric cancer; HWE, Hardy–Winberg equilibrium.